Clinical Trials

Rectal Neoplasms

NCT04920032 2026-04-13

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Phase 1 Recruiting

22 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

Phase 1/2 Recruiting

45 enrolled

Metastatic Gastric Adenocarcinoma

NCT07491159 2026-03-24

Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study

106 enrolled

Colorectal Neoplasms

NCT03223779 2026-03-12

Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer

Phase 1/2 Completed

52 enrolled

Colorectal Neoplasms

NCT05343013 2026-03-06

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

25 enrolled

Colorectal Neoplasms

NCT04511039 2026-03-02

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Phase 1 Recruiting

45 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Colorectal Neoplasms

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

100 enrolled

Colorectal Neoplasms

NCT04109924 2026-02-10

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

Phase 2 Completed

42 enrolled 12 charts

Phase NA Not yet recruiting

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07371871 2026-01-28

A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer

30 enrolled

Phase 2 Not yet recruiting

Advanced Gastric Cancer

NCT07286695 2026-01-21

Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer

292 enrolled

Colorectal Neoplasms

NCT03844620 2026-01-09

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

100 enrolled

Phase 2 Not yet recruiting

Colorectal Neoplasms

NCT07261709 2025-12-03

Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial

236 enrolled

Colorectal Neoplasms

NCT07212933 2025-10-08

RAK in GC

90 enrolled

Stomach Neoplasms

NCT07085169 2025-07-25

Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC

50 enrolled

Colonic Neoplasms

NCT05508737 2025-07-11

Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer

75 enrolled

Gastric and Gastroesophageal Junction Adenocarcinoma

NCT05201352 2025-05-30

TASKIN

160 enrolled

Colorectal Neoplasms

NCT06992648 2025-05-28

REGTAS-2

Phase 3 Recruiting

302 enrolled

Colorectal Neoplasms

NCT04450836 2025-03-30

SOREGATT

Phase 2 Terminated

234 enrolled

Phase 1 Not yet recruiting

Colorectal Neoplasms

NCT06882915 2025-03-19

Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study

20 enrolled

Phase 2 Not yet recruiting

Colorectal Neoplasms

NCT06872606 2025-03-12

SCRIPBOT

33 enrolled

Rectal Neoplasms

NCT03368963 2025-01-07

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

64 enrolled

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06711471 2024-12-02

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

31 enrolled

Gastric Cancer Adenocarcinoma Metastatic

NCT04294264 2024-11-18

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

50 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT06403709 2024-09-24

Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients

35 enrolled

Colorectal Neoplasms

NCT05356897 2024-09-19

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Phase 2 Withdrawn

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03981614 2024-08-22

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Phase 2 Completed

102 enrolled 11 charts

Colorectal Neoplasms

NCT05130060 2024-08-14

A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer

Phase 1 Completed

15 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06485713 2024-07-03

Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC

200 enrolled

Colorectal Neoplasms

NCT03992456 2024-05-21

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

12 enrolled 16 charts

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03317119 2024-04-08

Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

Phase 1 Completed

26 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06202001 2024-04-02

Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients

Phase 1/2 Recruiting

70 enrolled

Colorectal Neoplasms

NCT04660760 2024-04-01

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

116 enrolled

Clinical Stage III Gastric Cancer AJCC v8

NCT05007132 2024-02-15

Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

153 enrolled

Colorectal Neoplasms

NCT04074343 2024-02-02

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

Phase 1 Completed

20 enrolled 9 charts

Gastric Adenocarcinoma

NCT04072445 2023-08-09

Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

Phase 2 Completed

28 enrolled 20 charts

Bile Duct Neoplasms, Gallbladder Neoplasms

NCT04177602 2023-02-22

Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial

Phase 1/2 Terminated

10 enrolled